Ditemukan 32013 dokumen yang sesuai dengan query :: Simpan CSV
The COVID-19 pandemic situation has opened people's eyes to the importance of health, the increasing demand for health products has encouraged the logistics industry of PT X, which plays a role in the distribution of goods, to carry out overtime work to meet the high work intensity, this increases the risk of fatigue in the workplace which can reduce body function and have an impact on the health of workers and even the risk of errors in the workplace. Additionally, PT X lacks a fatigue risk management system, making it unable to do fatigue detection, thus this research aims to provide an overview of complaints and fatigue warehouse logistics workers at PT X year 2022, located in one of the DKI Jakarta region. Research design is a quantitative and qualitative with a cross-sectional study using questionnaire instruments, including the Fatigue Assessment Scale (FAS), NASA Task Load Index (TLX), and Pittsburgh Sleep Quality Index (PSQI) which were then analyzed univariately and triangulated the data with the results of field interviews towards several workers and the coordinator of each team. The results showed that there were 20 workers (37.04%) experiencing light fatigue, the majority of the others (62.96%) did not experience any, and none with severe fatigue, as for the most dominant fatigue risk factor found is the workers' sleep quantity with the majority of workers (83.33%) having sleep duration below the standard of 7 hours minimum
Latar belakang: Penyakit Jantung Koroner merupakan penyebab utama kematian. Sejak tahun 1993, Penyakit Jantung Koroner merupakan penyebab kematian utama pada masyarakat Indonesia. Salah satu faktor yang dapat menurunkan tingkat kematian PJK adalah faktor jaminan pembayaran asuransi kesehatan. Penelitian ini dilaksanakan untuk mengetahui pengaruh jaminan pembayaran asuransi kesehatan (ASKES dan ASKESKIN) terhadap ketahanan hidup pada penderita PJK yang dirawat di Cardivascular Care Unit (CVCU) Rumah Sakit M. Djamil Padang. Metodologi : Jenis penelitian dengan disain Kohort Retrospektif dengan survival analysis dengan menggunakan data sekunder yaitu catatan medis penderita PJK yang dirawat di CVCU Rumah Sakit M. Djamil Padang tahun 2007. Populasi penelitian adalah semua penderita PJK yang dirawat di CVCU Rumah Sakit M.Djamil Padang tahun 2007. Jumlah sampel penelitian adalah sebesar 398 orang penderita PJK. Hasil Penelitian : Ketahanan hidup penderita PJK dengan jaminan pembayaran asuransi kesehatan (ASKES dan ASKESKIN) lebih lama daripada penderita PJK dengan jaminan pembayaran pribadi. Setelah dikendalikan pengaruh variabel kovariat, maka didapatkan nilai HR = 0,75 ( 95% CI 0,42 ? 1,36 ) untuk penderita PJK dengan jaminan pembayaran ASKES dan nilai HR = 0,48 ( 95% CI 0,25 ? 0,91) untuk penderita PJK dengan jaminan pembayaran ASKESKIN. Kesimpulan dan Saran : Kesimpulan penelitian ini adalah ada perbedaan ketahanan hidup penderita PJK dengan jaminan pembayaran asuransi kesehatan dengan penderita PJK dengan jaminan pembayaran pribadi, dimana Ketahanan hidup penderita PJK dengan jaminan pembayaran asuransi kesehatan lebih lama daripada penderita PJK dengan jaminan pembayaran pribadi. Lebih lamanya ketahanan hidup penderita PJK dengan jaminan pembayaran asuransi kesehatan ASKESKIN daripada ASKES disebabkan adanya perbedaan obat standar yang dijamin oleh pihak asuransi. Untuk itu disarankan kepada pihak asuransi membuat kebijakan tentang persamaan jaminan pengobatan bagi peserta ASKES dan ASKESKIN. Bagi peserta asuransi agar dapat memanfaatkan jasa asuransi dengan melakukan kontrol kesehatan secara teratur.
Background : Coronary Heart Disease is a leading cause of death, and in Indonesia, it is a leading cause of death since 1993. Health insurance is one of the factors that can decrease the mortality rate due to this disease. This research was conducted to explore the effects of health insurance payment security (ASKES and ASKESKIN) on the survival of coronary heart disease client cared in Cardiovascular Care Unit (CVCU) of M.Djamil Hospital Padang. Methods : This research was retrospective cohort design with survival analysis using secondary data obtained from coronary heart disease client medical records in CVCU of M.Djamil Hospital Padang in 2007. Research population were all coronary heart disease clients cared in CVCU M.Djamil Hospital Padang in 2007, and 398 samples were obtained for this study. Results : Survival of coronary heart disease client with health insurance payment Security (ASKES and ASKESKIN) was longer than coronary heart disease client with out pocket payment. After controlled by covariate variable effect, the results revealed HR value were 0.75 (95% CI 0.42 ? 1.36) and 0.48 (95% CI 0.25 ? 0.91) for coronary heart disease client with ASKES insurance payment and for coronary heart disease client with ASKESKIN payment security respectively. Conclusion and Suggestion : It is concluded that Survival of coronary heart disease client with health insurance payment security was difference than coronary heart disease client with out pocket payment, however survival of coronary heart disease client with health insurance payment security was longer than coronary heart disease client with out pocket payment. The longer of the survival of coronary heart disease client with ASKESKIN insurance payment compared to ASKES is due to the difference of standard drugs that are guaranteed by insurance company, therefore it is recommended for insurance company to make policy about equality of treatment security for ASKES and ASKESKIN member. Insurance members are suggested to use the insurance service by performing regular health control.
Malignant pleural effusion (MPE) often appears in patients with lung cancer anddeteroriates prognosis of patients with mean survival rate of 6 months. This studyaims to look at the characteristics and survival of lung cancer patients with MPE(stage IIIB or IV) at Dharmais Cancer Hospital Jakarta in 2009-2013. Studydesign was longitudinal cohort with univariate and survival analysis. Sample waslung cancer patients with metastatic MPE based on cytology test or biopsy withcomplete medical record. Results showed average age of patients was 58.73; mostwere male, nonsmoker, and pensioner. Majority of patients had respiratorydisorder, adenocarcinoma cancer type, reached stage IV, and effusion in the rightlung. Approximately 68.5% of patients surviving 6 months after diagnosis andmedian survival were 12.5 months. IEC is needed for community; especiallypopulation with lung cancer risk, to help reducing number of new patients seekingtreatment after cancer reaches advanced stage.Keyword: malignant pleural effusion,characteristics, survival.
Penyakit HIV/AIDS merupakan masalah kesehatan di Indonesia. Masalah yang berkembang adalah karena angka morbiditas dan mortalitas yang masih tinggi, disebabkan antara lain karena keterlambatan mendapatkan pengobatan Anti Retroviral (ARV). Di Indonesia pengobatan ARV umumnya dimulai bila jumlah sel CD4 < 200 sel/mm 3 atau bila stadium klinis 3 atau 4. Informasi tentang pengaruh jumlah sel CD4 sebelum pengobatan ARV terhadap ketahanan hidup satu tahun pasien HIV/AIDS berdasarkan kelompok kategori 3 , 50- 3 dan > 200 sel/mm 3 , saat ini belum tersedia di Indonesia. Untuk mengetahuinya, maka dilakukan penelitian ini. Desain penelitian kohort retrospektif, dilakukan pengamatan terhadap kematian pada populasi dinamis selama satu tahun (366 hari), dari Januari 2005 hingga Januari 2010. Subjek penelitian 158 pasien HIV/AIDS berusia > 15 tahun, naïve dan mendapat regimen ARV lini pertama di RSPI Prof.DR.Sulianti Saroso pada tahun 2005-2010. Prosedur analisis ketahanan hidup menggunakan metode Kaplan-Meier (product limit), analisis bivariat dengan Log rank test (Mantel cox) dan analisis multivariat dengan cox regression / cox proportional hazard model. Penelitian ini mendapatkan probabilitas ketahanan hidup keseluruhan satu tahun pasien HIV/AIDS dengan pengobatan regimen ARV lini pertama adalah 0,86 (CI 95% 0,79-0,91). Incident rate kematian (Hazard rate) kelompok jumlah sel CD4 3 adalah 8/10.000 orang hari (29/100 orang tahun), kelompok jumlah sel CD4 50-3 adalah 3/10.000 orang hari (11/100 orang tahun) dan kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 2/10.000 orang hari (7/100 orang tahun). Hazard Ratio(HR)-adjusted kelompok jumlah sel CD4 <50 sel/mm 3 terhadap kelompok jumlah sel CD4 > 200 sel/mm 3 adalah 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), HR-adjusted kelompok jumlah sel CD4 50-3 terhadap kelompok jumlah CD4 > 200 sel/mm 3 adalah 1,7 (p= 0,48 ; CI 95% : 0,4-7.04). HR-adjusted pasien dengan TB 3,57 kali terhadap pasien tanpa TB (p=0,015 ; CI 95% : 1,27-9,99). Jumlah sel CD4 sebelum pengobatan ARV tidak mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Namun penelitian mendapatkan penyakit Tuberkulosis (TB) mempunyai pengaruh secara statistik terhadap ketahanan hidup satu tahun pasien HIV/AIDS yang mendapat regimen ARV lini pertama. Kata kunci: HIV/AIDS, jumlah sel CD4, pengobatan ARV, ketahanan hidup satu tahun.
HIV/AIDS disease is one of public health concerns in Indonesia. The growing issues related to high morbidity and mortality rate. This is due to such as lately initiated of Antiretroviral (ARV) therapy. In Indonesia ARV therapy is begun when the CD4 cell counts dropped below 200 cell/mm 3 or if clinical stadium fall into 3 rd th or 4 . Nowadays in Indonesia, Information about the influenced of baseline CD4 cell count to one year survival among patient HIV/AIDS with first line ARV regimen therapy, base on strata 3 , 50- 3 and > 200 cell/mm 3 was not available, therefore this research will be conducted. Study design was retrospective cohort, with one year (366 days) duration of observation to death, in dynamic population from January 2005 to January 2010. The subjects of study were 158 HIV/AIDS patients, with inclusion criteria: > 15 years old, naïve, and were treated by first line ARV regimen at RSPI Prof.DR. Sulianti Saroso in year 2005-2010. The procedures of survival analysis used Kaplan-Meier method (product limit), and Log rank test (Mantel cox) for bivariate analysis and cox regression / cox proportional hazard model for multivariat analysis. The overall of one year survival probability in HIV/AIDS patients with first line ARV regimen therapy was 0,86 (CI 95% 0,79-0,91). Incident rate of death (Hazard rate) in CD4 3 group was 8/10.000 persons days (29/100 persons years), in CD4 50-3 group was 3/10.000 persons days (11/100 persons years) and in CD4 > 200 cell/mm 3 group was 2/10.000 persons days (7/100 persons years). The Hazard Ratio(HR)-adjusted CD4 <50 cell/mm 3 patients compared to CD4 > 200 cell/mm 3 patients was 3,4 (p= 0,058 ; CI 95% : 0,96-12,16), the HR-adjusted CD4 50-3 patients compared to CD4 > 200 cell/mm 3 patients was 1,7 (p= 0,479 ; CI 95% : 0,4-7.04). HR- adjusted tuberculosis patients was 3,57 time more risk to death than patients without tuberculosis (p=0,015 ; CI 95% : 1,27-9,99). This study found that the baseline CD4 cell counts have not significant statistical associated to one year survival of HIV/AIDS patients with first line ARV regimen therapy, after has controlled to other independent variables. But this study found that tuberculosis has significant statistical association to one year survival of HIV/AIDS patients who received first line ARV regimen therapy. Keywords: HIV/AIDS, CD4 cell counts, treatment ARV, one year survival.
Metode: Penelitian ini merupakan studi analitik observatif dengan data kuantitatif. Sumber data berasal dari data sekunder berupa rekam medik RSUP Persahabatan tahun 2020. Dengan desain studi kasus kontrol, 50 sampel dalam kelompok kasus dan 100 sampel dalam kelompok kontrol dianalisis menggunakan SPSS dengan uji chi square, OR untuk mengetahui derajat hubungan antar variabel, dan p<0,05 sebagai batas kemaknaan.
Hasil: Usia ≤30 tahun (OR=0,30; p=0,019) dan kepatuhan minum obat (OR=6,64; p=0,000) memiliki hubungan statistik yang signifikan dengan kasus TB MDR di RSUP Persahabatan tahun 2020.
